BioWorld

Category Archives: Rare disease

The EMA’s Shambolic Handling of Glybera

May 7, 2012 – 2:58 pm

If you can’t see the wood for the trees the common sense response is to do a little thinning and let the light shine through.

Share
By Nuala Moran | Also posted in European Medicines Agency, Gene Therapy, Orphan disease | Tagged , , , | Comments (0)

He Said What?!?! Best Biotech Quotes of 2011

December 29, 2011 – 3:26 pm

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share
By Trista Morrison | Also posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, NDA, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Reimbursement, RNAi, siRNA, Stem cell, Supplemental new drug application, Uncategorized, venture captial | Tagged , , , | Comments (2)

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

December 28, 2011 – 6:11 pm
Share
By Jennifer Boggs | Also posted in Accelerated approval, Antibody, Big pharma, Biologic, Biosimilar, Biotech conferences, Biotechnology, BLA, Cancer, Cardiovascular, China, Clinic, Clinical Trial, Collaboration, Complete Response Letter, Deals, Drug Approval, European Medicines Agency, FDA, Financing, Gene Therapy, Genomics, Healthcare reform, immunotherapy, IND, Investigational New Drug Application, IPO, NDA, New Drug Application, Orphan disease, Patents, PDUFA, Personalized medicine, Pharmaceutical, Phase I, Phase II, Phase III, Pipeline, Preclinical, Reimbursement, RNAi, Uncategorized | Tagged , , , | Comments (1)